Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSE: Radiation During Osimertinib Treatment
NCT05089916Phase 2Active, not recruiting
- Sponsor
- AIO-Studien
- Start
- Jan 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Started Jan 2022; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05089916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089916.